Zhonghua Nei Ke Za Zhi. 2024 Apr 1;63(4):355-364. doi: 10.3760/cma.j.cn112138-20231104-00296.
Ultrasound-guided thermal ablation of papillary thyroid cancer (PTC) has been promoted in clinical practice over the past few years. Thermal ablation has the advantages of being minimally invasive, effective, and safe. However, current guidelines and consensus only focus on low-risk papillary thyroid microcarcinoma. With growing clinical application and accumulating scientific research in thermal ablation for PTC, there is considerable evidence to demonstrate that thermal ablation can treat larger PTC tumors and benefit more patients with PTC. To expand the indications and standardize the technical details and perioperative patient management for PTC ablation, experts from the Society of Tumor Ablation Therapy of the Chinese Anti-Cancer Association, the Ablation Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Chinese Medical Doctor Association College of Interventionalists Tumor Ablation Committee, and Chinese Bethune Spirit Research Association Endocrinology and Diabetes Branch Interventional Endocrine Committee discussed and developed a consensus on thermal ablation of PTC based on the latest research results. This consensus aims to promote the rapid development of thermal ablation for PTC in the clinic.
在过去几年中,超声引导下甲状腺乳头状癌(PTC)热消融术在临床实践中得到了推广。热消融具有微创、有效和安全的优点。然而,目前的指南和共识仅关注低风险甲状腺微小乳头状癌。随着PTC热消融术临床应用的不断增加和科学研究的积累,有大量证据表明热消融可以治疗更大的PTC肿瘤,并使更多PTC患者受益。为了扩大PTC消融的适应证,规范技术细节和围手术期患者管理,中国抗癌协会肿瘤消融治疗专业委员会、中国临床肿瘤学会(CSCO)消融专家委员会、中国医师协会介入医师分会肿瘤消融专业委员会以及中国白求恩精神研究会内分泌与糖尿病学分会介入内分泌学组的专家们基于最新研究成果,讨论并制定了PTC热消融的共识。该共识旨在推动PTC热消融术在临床上的快速发展。
Zhonghua Nei Ke Za Zhi. 2024-4-1
J Cancer Res Ther. 2020-9
Front Endocrinol (Lausanne). 2022
Front Endocrinol (Lausanne). 2025-6-4
Front Endocrinol (Lausanne). 2024